FindMyKOL
Clinical trialNCT02744053Active, not recruitingEarly phase 1Interventional

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

SponsorM.D. Anderson Cancer CenterEnrollment96Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeTriple-Negative Breast Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

  • Md Anderson in Katy

    Houston, Texas, United States

  • Memorial Hermann Memorial City Medical Center

    Houston, Texas, United States

  • Md Anderson League City

    Nassau Bay, Texas, United States

  • Md Anderson in Sugar Land

    Sugar Land, Texas, United States

  • Md Anderson in the Woodlands

    The Woodlands, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Technetium
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Nov 2016
Primary completion
30 Apr 2028
Completion
30 Apr 2028
Last update posted
7 Oct 2026
Registered enrollment
96
Registry id
NCT02744053

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.